Multicentre, randomized, parallel, double-blind, vehicle controlled study to evaluate the efficacy and safety of Actikerall solution in the field-directed treatment of actinic keratoses grade I to II (field cancerization)

Trial Profile

Multicentre, randomized, parallel, double-blind, vehicle controlled study to evaluate the efficacy and safety of Actikerall solution in the field-directed treatment of actinic keratoses grade I to II (field cancerization)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Fluorouracil/salicylic-acid (Primary)
  • Indications Actinic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Almirall Hermal GmbH; Almirall S.A.
  • Most Recent Events

    • 01 Mar 2017 Results (n=163) published in the Dermatology and Therapy
    • 05 Sep 2016 Primary endpoint has been met. (Percentage of patients with complete clinical clearance (CCC) of AK lesions in the treatment field at 8 weeks post last treatment [Timepoint: 8 weeks post last treatment ])
    • 05 Sep 2016 According to an Almirall media release, results from this study have been presented at the 16th World Congress on Cancers of the Skin & 12th Congress of the European Association of Dermato Oncology (EADO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top